Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation for presentation of Pricer’s interim report for the third quarter 2021

Pricer AB will present its interim report for the third quarter 2021 in an audiocast on October 22 at 13.00 CET.According to the financial calendar, Pricer will publish the report for the third quarter 2021 on Friday October 22 at approximately 8.30 CET. Pricer hereby invites to a presentation of the report on the same day. Pricer’s CEO Helena Holmgren will present the report and answer questions. Date: Friday October 22, 2021 Time: 13.00 CET Link to the audiocast: https://financialhearings.com/event/13243 For further information, please contact: Helena Holmgren, President

NENT Group names ‘Elvira’ as latest Danish Viaplay Original drama

· Offbeat drama series stars Sara Klein in debut leading role · ‘Elvira’ adapted from acclaimed novels by Anne-Sophie Lunding-Sørensen · NENT Group to premiere at least 60 Viaplay Originals in 2022 A first-time star portraying Denmark’s unlikeliest detective is the premise for ‘Elvira’, the next Danish Viaplay Original by Nordic Entertainment Group (NENT Group), one of the world’s fastest growing streaming companies. Starring rising talent Sara Klein and adapted from an acclaimed series of novels, the offbeat drama joins international hits such as ‘Face to Face’ and ‘Those Who Kill’

Navamedic ASA extends exclusive distribution rights for Mysimba in the Nordics

Oslo, 12 October 2021 – Navamedic ASA (OSE: NAVA) today announces it has exercised a five-year extension of its exclusive distribution rights for Mysimba® in the Nordics. Mysimba® is one of the fastest growing products in Navamedic’s portfolio, displaying sales growth of 89% in first half 2021 compared to the same period last year.Mysimba® is the first obesity treatment of its kind, combining both an oral medicin with a digital and custom-made patient support program to maximise patients’ success in treatment. Mysimba® reduces hunger and cravings, and provides control over food intake,

Invitation to presentation of Humana's report on third quarter 2021

Humana's interim report for the third quarter and nine-month period 2021 results will be published at 08:00 CET on November 11, 2021. A web-cast telephone conference will be held at 09:00 CET the same day.The webcast, where CEO and President Rasmus Nerman and CFO Noora Jayasekara will present the report, will be accessible at Humana's website www.humanagroup.com. The presentation material will be published on the website before the conference starts. The webcast, and later the recorded version of the webcast, will also be available at www.financialhearings.com.To participate in the

iLOQ brings innovation and sustainable thinking to the World Economic Forum event week

The World Economic Forum (WEF) Annual Meeting will take place from 17–21 January 2022 in Davos-Klosters, Switzerland, under the theme Working Together, Restoring Trust. The WEF’s mission is to bring together the most significant leaders from all sectors of global society to identify the best ways of addressing the world’s most pressing challenges. An important topic at next year’s event will be setting the agenda for shaping a more sustainable future. Digital locking and mobile access solutions company, iLOQ, is proud to be participating in the global event and contributing to the

Salipro Biotech enters into a collaboration and license agreement with AbCellera

Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro® Platform for antibody discovery against GPCRs, ion channels, and transporters The collaboration enables AbCellera to access Salipro Biotech’s unique expertise and its Salipro® platform technology to generate stable antigens for challenging membrane protein drug targets for antibody discovery.Stockholm, Sweden, October 12, 2021 – Swedish biotech company Salipro Biotech AB today announced that it has entered into a collaboration and licensing agreement with AbCellera for access to

BioStock: Spago Nanomedical’s CDO is in place

Recently, First North-listed, Spago Nanomedical announced the recruitment of Paul Hargreaves as Chief Development Officer to oversee the company’s clinical development, with a particular focus on the Tumorad project and the leading candidate drug SN201. BioStock contacted Hargreaves to hear about his background, the new role and his expectations on the task ahead.Read the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se: https://www.biostock.se/en/2021/10/spago-nanomedicals-cdo-is-in-place/ This is a press release from BioStock - Connecting Innovation & Capital.

NOTICE TO ATTEND ANNUAL GENERAL MEETING IN BUILDDATA GROUP AB

The shareholders of BuildData Group AB, reg.no 559136-0317 (the “Company”) are hereby summoned to the annual general meeting on Thursday, 11 November 2021 to be held by postal voting only.   In view of the current situation and considering the risk for spreading the coronavirus, the Board of Directors have decided, that the meeting shall be held without physical presence by shareholders exercising their right to vote by postal voting, in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other

WindowMaster announces strong growing pipeline and record order intake but increased inflation and delayed execution results in reduced EBITDA outlook for 2021

Tuesday, October 12, 2021 09:00 CET Company Announcement No. 19-2021 – Inside InformationVedbæk, October 12, 2021 Highlights from 2021-Q3 YTDWindowMaster continues its growth in opportunity pipeline – both in numbers but more important growth in value. The order intake also grew in Q3 YTD 2021 – with a 14% increase compared to the same period in 2020 (12% to 2019). The 12-month rolling order intake is at 218 MDKK – resulting in a record high order back log. Overall demand is intact and growing. · Net sales for 2021-Q3 YTD ended at 157m DKK representing a 15% increase compared

Finnfund and University of Helsinki to invest together into microfinancing in Africa and Asia

Finnfund, a Finnish development financier and impact investor, announce today a EUR 10 million debt facility commitment to the Advans Group , one of the leading international microfinance group serving over one million clients in nine countries: Cambodia, Cameroon, Ghana, Democratic Republic of Congo, Cote d’Ivoire, Pakistan, Nigeria, Tunisia, and Myanmar. University of Helsinki participates in this investment with Finnfund. Through this funding, Finnfund and University of Helsinki aim to generate funding for micro and small businesses and promote

Verifying results of efficacy for RCD405

Respiratorius reports positive preclinical milestone results from an ex vivo efficacy study of RCD405. The study has been conducted at a contract laboratory specialised in performing efficacy studies using human biospecimens, such as human lung tissue.In the study, RCD405 has been evaluated together with well-known bronchodilatory compounds in airway tissue from different species, i. e. rat, dog, and human. In all experiments a concentration-dependent dilatory effect of RCD405 was observed after induced constriction. In human airway tissue the relaxation was substantial and at least in the

BioStock Studio: Xintela expands to venous leg ulcers

Xintela has broadened the clinical development of its stem cell product XSTEM to include venous leg ulcers, the most common form of difficult-to-heal wounds in humans. Together with the Burn Centre at Linköping University Hospital, the company has shown that XSTEM provides good wound healing in a preclinical model. The next step for the company will be to apply for a clinical study in patients with venous leg ulcers, a study that Professor Folke Sjöberg from the Burn Centre tells us more about below.Watch the interview with Professor Folke Sjöberg at biostock.se: https://www.biostock.se/

TePe introduces TePe Supreme™ – a sustainable toothbrushing option

Following the introduction of TePe’s sustainable interdental brushes and speciality brushes, the TePe Supreme toothbrush is now relaunched as yet another step on TePe’s journey towards climate neutral product and packaging.“Climate action is one of our biggest concerns, and we know that renewable energy and materials have a significant impact on reducing emissions. At TePe, we are constantly working to broaden the offer of sustainable oral health products for consumers. Today, the main part of our range is made from sustainable sources and produced by 100% renewable energy”, says Helena

Martin Linde leaves the board of AcouSort for health reasons

Aegirbio announced yesterday that CEO Martin Linde is on sick leave. Martin Linde has also chosen to leave the board of AcouSort to focus on his recovery.The Board will shortly convene an Extraordinary General Meeting to elect a new Board member to replace Martin. The company would like to thank Martin for his great commitment and strong efforts over the years and wishes him a rapid recovery. For further information on AcouSort, please contact: Torsten Freltoft, CEOTelephone: +45 2045 0854E-mail: torsten.freltoft@acousort.com About AcouSort AcouSort AB (corporate

Invitation to presentation of Bulten’s Q3 report 2021

Bulten’s interim report for the period January – September 2021 will be published on Thursday 28 October 2021 at 13:30 CET.A presentation for analysts, media and investors will be held the same day at 15:30 CET during a webcasted teleconference. The report will be presented by President and CEO Anders Nyström and CFO Anna Åkerblad. The presentation will be held in English and include a Q&A session. Date: Thursday, October 28Time: The report will be published at 13:30 CET and the teleconference starts at 15:30 CET To participate in the teleconference, please dial in 5 minutes before

Metso Outotec to publish its Interim Report for January-September 2021 on Tuesday, November 2, 2021

Metso Outotec Corporation’s press release on October 12, 2021, at 09:30 a.m. EESTMetso Outotec’s Interim Report for January-September 2021 will be published on Tuesday, November 2, 2021 at about 9:00 a.m. EET and can be found on the Metso Outotec website .  Metso Outotec’s President and CEO Pekka Vauramo and CFO Eeva Sipilä will present the results in an audiocast and a conference call for analysts and investors on the same day at 13:00 p.m. EET.  The audiocast can be followedat the company’s website 

Modus Therapeutics - Symbiosis Pharmaceutical Services Starts Producing Sevuparin for Modus’ Future Clinical Development in Sepsis/septic shock

STOCKHOLM, SWEDEN – 12 October 2021: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with high unmet medical needs, announces that Symbiosis Pharmaceutical Services Ltd (“Symbiosis”), a specialist contract manufacturing organization (CMO), has started manufacturing sevuparin drug product securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation. This follows a recent drug supply agreement between Modus and Symbiosis covering the drug product needs for the Phase II

Inhalation Sciences and Karolinska Institutet renew partnership with new validation work and Mars dust study

(Stockholm, Sweden, 12 October 2021) In a renewed partnership Karolinska Institutet (KI) in Stockholm will help validate ISAB’s new XposeALI® MP (Micro Perfusion) tool, including using it to test a Mars dust surrogate for the European Space Agency as part of exploring future manned missions to Mars. XposeALI® MP is a highly automated new iteration of ISAB’s current cell culturing module and is expected to make in vitro lung studies simpler, more consistent and more cost-effective – including for biologics, a key priority area for inhaled drug developers.On Friday 8 October ISAB renewed its

Aarhus University Hospital, a Globally Leading Medical Institution, Begins Use of IRRAS’ IRRAflow System and Initiates Clinical Study to Validate its Efficacy

· Aarhus University Hospital in Denmark commenced its commercial use of the IRRAflow system for patients with intracranial bleeding · The hospital’s treatment experience with IRRAflow will be tracked and compared to treatment with traditional passive drainage as part of the ACTIVE clinical studyStockholm, October 12, 2021 - IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Aarhus University Hospital in Aarhus, Denmark, one of the world's leading medical institutions, has initiated commercial use

Quickbit announces changes in Group management

Quickbit continues the strategy of broadening the company's target groups. The new phase, which began in the middle of the previous year, meant that the company broadened its offering to also include products aimed at the consumer market. Quickbit will develop easily accessible and secure financial services based on blockchain technology, aimed at both merchants and consumers. To better meet the challenges of the new phase and support the implementation, Quickbit is making changes in the Group management team.Simon Afeworki goes from a role as Head of Finance to a newly established role as

Akobo Minerals receives very positive results from its metallurgical testwork with potential for greater than previously expected revenue generation

Akobo Minerals has received the testwork results from the Peacocke and Simpson Laboratory. The positive results of these gold extraction tests give potential for greater than expected revenue generation to that proposed in the Scoping Study (27.09.2021), at similar operating costs.   The metallurgical testwork gives an indication of how much gold is expected to be recovered as if the cores/bulk samples had been treated with conventional gravity recovery and cyanide leaching unit operations. Samples were taken from a total of 3 holes drilled at Segele to generate  248kg for testwork

BioStock: RhoVac brings in Stifel as transaction advisor for RV001

Biotech company RhoVac has started the autumn by reaching several important milestones in its work with drug candidate RV001. Next year’s readout of  the phase IIb study BRaVac is rapidly approaching and the company is now contracting Investment Bank Stifel Nicolaus Europe as an advisor on the subsequent exit or partnership process. BioStock spoke to RhoVac’s CEO Anders Månsson to find out more.Read the full article at biostock.se:https://www.biostock.se/en/2021/10/rhovac-brings-in-stifel-as-transaction-advisor-for-rv001/This is a press release from BioStock - Connecting Innovation &

Paulig and Lantmännen announce sustainable farming partnership

Today, the international food and beverage company Paulig announced a sustainable farming partnership with Lantmännen, a Swedish agricultural cooperative. As part of the collaboration, Swedish farmers will adopt even more sustainable cultivation methods within the framework of Lantmännen’s program for Farming of the Future: Climate & Nature. As of harvest 2022, Lantmännen Cerealia will supply Paulig with 17,000 tons of wheat flour cultivated in accordance with the program, reducing the climate impact by as much as 30 percent*. The flour will be used to annually produce 400 million Santa Maria

Read original

OKEA decides to halt further development of Vette discovery due to insufficient financial robustness

OKEA, as operator of the Vette licence (40% Working Interest (WI)), has decided to propose to the licence partners not to develop the Vette discovery further, due to the project’s insufficient financial robustness. OKEA took over operatorship of the licence earlier this year and has been maturing the discovery towards a DG2 decision.  OKEA has also worked to improve the economics of the Grevling/Storskrymten discoveries along with the license partners over the last few years. Although significant reductions in break-even cost have been achieved, it is deemed insufficient to warrant a

There are no items matching the current filter
There are no more items matching the current filter
Back to top